Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Braeburn's Buprenorphine Candidate Faces Safety Gauntlet At US FDA Panel

31 Oct 2017

• By Michael Cipriano

Related Content

Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?

29 Oct 2017

Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says

26 Oct 2017

US FDA May Change Opioid Labeling To Limit Dispensing By Indication

15 Sep 2017

Related Companies

Apple Tree Partners

Indivior plc

Additional Topics

United States Advisory Committees Drug Review Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.